• why us?
  • Case Studies
  • EU, US and Japan Payer Research for a novel immunotherapy in advanced RCC


Our client was developing novel, precision immunotherapy, delivering individualized treatments that recognized each patient’s disease. Its lead product was in Phase III clinical development and the client was preparing for commercialization in key markets. Unlike other cellular immunotherapies, the clients platform entailed the manufacture of multiple cryopreserved doses of individualized therapeutic product, therefore the supply chain was complex. The client had conducted limited analysis of the payer landscapes in the key markets and therefore required this urgently to inform the detailed commercial strategy and tactical marketing plans. Furthermore, its clinical trials to date had not collected any Quality of Life (QOL) data, and we proposed this to be an issue to be addressed as well.


Alacrita provided support through:

  • Developing a target therapeutic profile (TPP) suited for a payer audience
  • Conducted 30 primary payer research in the EU, US and Japan
  • Assessed gaps in the evidence generation program versus payer ‘value drivers’

We provided a written report summarising payer feedback, specifically:

  • Payers’ level of focus on the indication, perceived budget impact and cost tracking
  • Payers’ view of the level of unmet need in the indication
  • The assessment process for coverage and reimbursement
  • Impact of labeling scenarios on pricing and reimbursement
  • Key payer value elements (based on reaction to product profile)
  • Open and closed pricing analysis
  • The evidence required to support the targeted price range
  • Perception of existing cell and gene therapies


View Additional Immunotherapy Case Studies



For more information on how we can assist your project, please contact us.

Related Case Studies